FDA Approves sNDA for Abuse Deterrent, Extended-Release Oxycodone – MD Magazine

The US Food and Drug Administration has approved a supplemental new drug application (sNDA) for an abuse-deterrent, extended-release oxycodone formula (Xtampza, Collegium Pharmaceutical) for the management of severe pain that requires daily, long-term opioid treatment.

The approval resulted in 3 main changes to the label. Pharmacokinetic, comparative data for the extended-release drug will be added, showing a comparison with the abuse-deterrent version (more…)

LI pain doctor sentenced to 50 months in oxycodone case – Newsday

A Long Island doctor who pleaded guilty to conspiracy to distribute oxycodone was sentenced Friday to 50 months in prison in federal court in Central Islip.

Dr. Noel Blackman also was ordered to forfeit $536,000, fined $15,000, and ordered to serve 3 years’ supervised release, if he is not deported to Guyana, by U.S. District Judge Joanna Seybert. Blackman, 69, lived in (more…)

FDA Approves Abuse Deterrent IR Oxycodone – Pain Medicine News

family:arial,sans-serif”> family:arial,sans-serif”>
FDA Approves Abuse Deterrent IR Oxycodone
Pain Medicine News
The FDA has approved RoxyBond abuse-deterrent oxycodone hydrochloride tablets (RoxyBond, Inspirion) for the management of pain severe enough to require an opioid analgesic, and when alternative treatments are inadequate. The drug has multiple …

More:
FDA Approves Abuse Deterrent IR Oxycodone – Pain Medicine News